The invention relates to in vitro methods for establishing a prognosis concerning the progress of a patient diagnosed with colorectal cancer after the administration of a therapy, monitoring the effect of said therapy on the patient or predicting the clinical response of the patient to the therapy in terms of basal expression levels. Said methods comprise quantifying the expression level of the TFF3 gene or the protein encoded by said gene.
